A new approach to trial rescue
If your trial fails to meet its Phase II or Phase III endpoints, you can be faced with difficult choices. Either abandoning or deprioritizing the product. Both of these options have significant consequences for your business and the patients you strive to help.
Today, advanced analytics such as machine learning are enabling new, more precise views into the data, identifying predictive biomarkers and generating sub-groups based on characteristics that might yield different results.
Capturing this data can be the difference between a successful trial and a discarded product.